- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00821886
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
12. prosince 2014 aktualizováno: SCRI Development Innovations, LLC
Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
In this phase II trial the investigators propose to evaluate ixabepilone in combination with carboplatin and trastuzumab as neoadjuvant therapy in locally advanced breast cancer patients.
Patients with early stage, HER2-positive breast cancer will receive six cycles of neoadjuvant treatment with ixabepilone, carboplatin, and trastuzumab every three weeks prior to surgery; after surgery, patients will continue treatment with trastuzumab every three weeks until week 52.
Concomitant with the post-operative trastuzumab treatment, patients with hormone receptor-positive tumors will receive anti-estrogen treatment.
Also, after the completion of chemotherapy, patients may receive radiation treatment at the discretion of their physician.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
60
Fáze
- Fáze 2
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Florida
-
Fort Myers, Florida, Spojené státy, 33901
- Florida Cancer Specialists
-
-
Georgia
-
Augusta, Georgia, Spojené státy, 30901
- Medical Oncology Associates of Augusta
-
-
Indiana
-
Terre Haute, Indiana, Spojené státy, 47802
- Providence Medical Group
-
-
Maine
-
Portland, Maine, Spojené státy, 04101
- Mercy Hospital
-
-
Maryland
-
Bethesda, Maryland, Spojené státy, 20817
- Center For Cancer And Blood Disorders
-
Bethesda, Maryland, Spojené státy, 20817
- National Capital Clinical Research Consortium
-
-
Michigan
-
Grand Rapids, Michigan, Spojené státy, 49503
- Grand Rapids Clinical Oncology Program
-
-
Missouri
-
Chesterfield, Missouri, Spojené státy, 63017
- St. Louis Cancer Care
-
-
New Jersey
-
Morristown, New Jersey, Spojené státy, 07960
- Hematology Oncology Associates of Northern NJ
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45242
- Oncology Hematology Care
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37023
- Tennessee Oncology, PLLC
-
-
Virginia
-
Richmond, Virginia, Spojené státy, 23235
- Virginia Cancer Institute
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Female and male patients ≥18 years of age.
- Histologically confirmed adenocarcinoma of the breast.
- Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-T3, N1-N2, M0). (T1N0M0 lesions are excluded.)
- Patients who have no clearly defined palpable breast mass or axillary lymph nodes but are radiographically measurable are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. In these patients, radiographic tumor measurements need to be repeated after 3 cycles and prior to surgery.
- Positive HER2 status (overexpression and/or amplification of HER2 in the primary tumor) as defined by: IHC 3+ or fluorescence in situ hybridization (FISH) positive (ratio >2.2) testing. Documentation of the HER2 results must be available at the time of study enrollment.
- An ECOG (Eastern Cooperative Oncology Group) performance score of ≤2
Normal bone marrow function as defined by:
- absolute neutrophil count (ANC) >1,500/µL;
- platelets >100,000/µL;
- hemoglobin >10 g/dL.
- Normal hepatic and renal function.
- Left ventricular ejection fraction (LVEF) within the institutional limits of normal, whichever is lower, as measured by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO).
- Life expectancy > 12 weeks.
- Estrogen and progesterone (or estrogen alone) receptor status in the primary tumor known or pending at the time of study enrollment.
- For women of childbearing potential, negative serum pregnancy test within 7 days prior to starting treatment.
- For women of childbearing potential, agreement to use a method of contraception that is acceptable to their physician from time of first signing the informed consent until at least 3 months after the last dose of study drug. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Patient agreement to discontinue breast-feeding, if applicable, during study treatment. Men enrolled in the study must also agree to use a method of contraception that is acceptable to their physician during their study participation.
- For patients with previous invasive cancers (including breast cancer) treated with curative intent, completion of chemotherapy or radiation therapy more than 5 years prior to enrollment for this study and no evidence of recurrent disease. Patients may be receiving anti-estrogen hormonal therapy prescribed for previous invasive breast cancer as long as the diagnosis of invasive cancer was made more than 5 years prior to study enrollment. Patients may be using anti-estrogen hormonal therapy at the time of current diagnosis but must discontinue this therapy before beginning study treatment.
- For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- Previous treatment for this breast cancer.
- Evidence of metastatic disease.
- Prior radiation that included ≥30% of major bone marrow-containing areas.
- Women who are pregnant or breastfeeding.
- Neuropathy (motor or sensory) ≥grade 1 at study entry.
History of significant cardiac disease or cardiac risk factors or the following:
- uncontrolled arrhythmias
- poorly controlled hypertension (e.g., systolic blood pressure [BP]> 150 mmHg or diastolic BP >100 mmHg) in spite of optimal medical management
- angina pectoris requiring antianginal medication or unstable angina within the previous 6 months
- history of documented congestive heart failure (CHF)
- any documented myocardial infarction within the previous 6 months
- clinically significant valvular heart disease
- current use of medications (e.g., digitalis, beta-blockers, calcium channel-blockers) that alter cardiac conduction, if these medications are administered for the management of cardiac arrhythmia, angina, or CHF. If these medications are administered for other reasons (e.g., hypertension), the patient may be eligible.
- patients with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG unless ECHO or MUGA scan within the last 3 months demonstrates that the LVEF is ≥ institutional lower limit of normal.
- Symptomatic intrinsic lung disease.
- Active malignancy, other than superficial basal cell carcinoma, superficial squamous (skin) cell carcinoma, carcinoma in situ, or non-invasive breast cancer, within the past 5 years.
- Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection >grade 2.
- Mental condition or psychiatric disorder rendering the subject unable to understand the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving a reasonable suspicion of a disease or condition that contraindicates the use of a study agent or that may affect the interpretation of the results or renders the subjects at high risk from treatment complications.
- Chronic use of CYP3A4 inhibitors and use of the following strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole. Use of these agents must be discontinued at least 72 hours prior to initiation of study treatment.
- Received chemotherapy for any indication within the 5 years preceding study enrollment.
- Prior treatment with trastuzumab or any other anti-HER2 agent for any indication.
- Concurrent treatment with any other anti-cancer therapy.
- Concurrent radiation therapy during neoadjuvant study treatment.
- Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to study enrollment.
- Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention of breast cancer. These agents must be discontinued prior to study enrollment.
- Participation within the previous 30 days in a study with an experimental drug.
- Known or suspected allergy to Cremophor EL (polyoxyethylated castor oil), a drug formulated in Cremophor EL such as paclitaxel, or any other agent given in the course of this trial.
- Inability or unwillingness to comply with study procedures including those for follow-up.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Ixabepilone/Trastuzumab/Carboplatin
Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
|
Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
Ostatní jména:
Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period.
Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
Ostatní jména:
Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Pathologic Complete Response (pCR)
Časové okno: average18 months
|
Proportion of patients who do not exhibit residual invasive breast cancer in breast or axillary lymph nodes at time of surgery
|
average18 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of Subjects With Adverse Events as a Measure of Safety and Toxicity
Časové okno: Day 1 of each 3 week cycle up to 6 cycles , and every 9 weeks post-surgery until treatment discontinuation
|
Assessment based on the frequency of treatment-related adverse events according to NCI CTCAE criteria v3.0.
|
Day 1 of each 3 week cycle up to 6 cycles , and every 9 weeks post-surgery until treatment discontinuation
|
Disease-free Survival
Časové okno: expected average 18 months
|
Defined as the interval from the first date of study treatment until the date of tumor recurrence or death from any cause
|
expected average 18 months
|
Overall Survival
Časové okno: approximately 48 months
|
Defined as the time between Day 1 Cycle 1 to date of death from any cause.
|
approximately 48 months
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Vyšetřovatelé
- Studijní židle: Denise Yardley, M.D., SCRI Development Innovations, LLC
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. února 2009
Primární dokončení (Aktuální)
1. července 2011
Dokončení studie (Aktuální)
1. října 2014
Termíny zápisu do studia
První předloženo
12. ledna 2009
První předloženo, které splnilo kritéria kontroly kvality
12. ledna 2009
První zveřejněno (Odhad)
14. ledna 2009
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
22. prosince 2014
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
12. prosince 2014
Naposledy ověřeno
1. prosince 2014
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- SCRI BRE 139
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Rakovina prsu
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital a další spolupracovníciDokončenoPrůvodce klinickou aplikací Conebeam Breast CTČína
-
Gangnam Severance HospitalNáborHER2 Enriched Subtype Cancer Breast, Herzuma, PAM50 StudyKorejská republika
-
BioNTech SESeventh Framework ProgrammeDokončenoRakovina prsu (Triple Negative Breast Cancer (TNBC))Švédsko, Německo
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)NáborAnatomický karcinom prsu stadia II AJCC v8 | Anatomický karcinom prsu stadia III AJCC v8 | Rané stadium karcinomu prsu | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Emory UniversityNational Cancer Institute (NCI)StaženoPrognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v mozku | Metastatický karcinom prsu | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktivní, ne náborAnatomický karcinom prsu stadia IV AJCC v8 | Prognostický karcinom prsu stadia IV AJCC v8 | Metastatický maligní novotvar v kosti | Metastatický maligní novotvar v lymfatických uzlinách | Metastatický maligní novotvar v játrech | Metastatický karcinom prsu | Metastatický maligní novotvar v plicích | Metastatický... a další podmínkySpojené státy, Kanada, Saudská arábie, Korejská republika
Klinické studie na Ixabepilone
-
Weill Medical College of Cornell UniversityBristol-Myers SquibbDokončenoMetastatický karcinom prsuSpojené státy
-
R-PharmNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterDokončenoNespecifikovaný dospělý solidní nádor, specifický pro protokolSpojené státy
-
National Cancer Institute (NCI)DokončenoLymfom | Rakovina tenkého střeva | Nespecifikovaný dospělý solidní nádor, specifický pro protokolSpojené státy
-
Cedars-Sinai Medical CenterBristol-Myers SquibbUkončenoUrogenitální novotvary | Adenokarcinom | Karcinom | Novotvary, žlázové a epiteliální | Genitální novotvary, muži | Novotvary prostaty | Onemocnění prostaty | Onemocnění pohlavních orgánů, mužSpojené státy
-
R-PharmDokončenoSolidní malignitySpojené státy
-
Eisai Inc.Dokončeno
-
R-PharmDokončeno
-
R-PharmDokončenoNovotvary žaludkuKorejská republika, Tchaj-wan, Japonsko, Singapur, Hongkong